MedTrace Logo

A Clinical Trial of Fluvoxamine for Melancholia

NCT04160377 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-04-12

No results posted yet for this study

Summary

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for endogenous depression. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.

Conditions

  • Depressive Disorder
  • Endogenous Depression
  • Melancholia

Interventions

DRUG

Fluvoxamine

Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .

Sponsors & Collaborators

  • Lingjiang Li

    lead OTHER

Principal Investigators

  • Lingjiang Li, MD · Mental Health Institute, the Second Xiangya Hospital of Central South University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2022-06-30
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04160377 on ClinicalTrials.gov